Bahija Jallal
Chief Executive Officer at IMMUNOCORE HOLDINGS PLC
Net worth: 2 M $ as of 31/03/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Zheng Bin Yao | M | 58 |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | 12 years |
| Ahmed Hamdy | M | 59 | 11 years | |
| Elizabeth Tallett | F | 74 | 11 years | |
| Marc Dunoyer | M | 71 | 11 years | |
| Jim Kastenmayer | M | 52 | 9 years | |
| David Berman | M | - |
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | 9 years |
| Travis Coy | M | 43 |
Immunocore Ltd.
 Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The private company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | 5 years |
| Stuart Lutzker | M | 63 | 3 years | |
| Roy Herbst | M | 60 |
Immunocore Ltd.
Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The private company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | 3 years |
| Kristine Peterson | F | 64 |
Immunocore Ltd.
Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The private company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | 7 years |
| John Bell | M | 71 | 9 years | |
| Peter Ratcliffe | M | 69 |
Immunocore Ltd.
Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The private company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | 4 years |
| Gail Boudreaux | F | 63 | 7 years | |
| Lily Hepworth | F | - | 6 years | |
| Ronald Penczek | M | 59 | 19 years | |
| John Saia | M | 51 | 4 years | |
| Blair Todt | M | 56 | 4 years | |
| Robert Dixon | M | 68 | 13 years | |
| Stephen V. Tanal | M | - | 3 years | |
| Antonio Neri | M | 56 | 7 years | |
| Deborah DiSanzo | F | 64 | 7 years | |
| Deanna Strable-Soethout | F | 55 | 2 years | |
| Robert Perez | M | 59 | 5 years | |
| Winston Kung | M | 48 | - | |
| Barbara White | M | 73 |
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD.
The Johns Hopkins University
| 5 years |
| Michael Bell | M | 55 | 3 years | |
| Nazneen Rahman | M | - | 7 years | |
| Mohammed Dar | M | - |
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | 11 years |
| Shu Kam Mok | M | 63 | 5 years | |
| Chris Rigg | M | - | - | |
| Meghan Joyce | F | 39 | 3 years | |
| Christian Nolet | M | 67 | 1 years | |
| Dustin Wilcox | M | - | 6 years | |
| Siddharth Kaul | M | 63 |
Immunocore Ltd.
Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The private company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | 2 years |
| Beth Marek | F | - |
The Johns Hopkins University
| - |
| Robin LaChapelle | F | 51 | 6 years | |
| Pascal Soriot | M | 64 | 12 years | |
| Jill A. Becher | F | - | - | |
| R. Clark | M | 71 | 10 years | |
| Philip Broadley | M | 63 | 7 years | |
| Ryan Schneider | M | 54 | 5 years | |
| Vijaya Gadde | F | 49 | 4 years | |
| Mark Kaye | M | 45 | 1 years | |
| Ramiro Peru | M | 68 | 20 years | |
| Paula Boggs | F | 64 |
The Johns Hopkins University
| - |
| Mike Gutch | M | 58 |
The Johns Hopkins University
| 4 years |
| Myrtle Potter | F | 65 | 3 years | |
| Pam Cheng | F | 53 | 9 years | |
| Lewis Hay | M | 68 | 11 years | |
| James Healy | M | 58 | 1 years | |
| Susan DeVore | F | 65 | 3 years | |
| Sherilyn McCoy | F | 65 | 7 years | |
| David Hodgson | M | 67 |
The Johns Hopkins University
| - |
| Carl Gordon | M | 59 | 2 years | |
| Naneen Neubohn | F | - |
The Johns Hopkins University
| - |
| Kent Calder | M | - |
The Johns Hopkins University
| - |
| Paul M. Ness | M | 78 |
The Johns Hopkins University
| 45 years |
| Bonnie Windsor | F | - |
The Johns Hopkins University
| - |
| Charlie Scharf | M | 59 |
The Johns Hopkins University
| - |
| Dorothy Sheppard | F | - |
The Johns Hopkins University
| - |
| Jennifer Calhoun | F | - |
The Johns Hopkins University
| - |
| Julia Buick | F | - |
The Johns Hopkins University
| - |
| Rick Inglis | M | - |
The Johns Hopkins University
| - |
| Kristina Snyder | F | - |
The Johns Hopkins University
| - |
| Gail McGovern | F | 72 |
The Johns Hopkins University
| - |
| Sobhi Batterjee | M | - |
The Johns Hopkins University
| - |
| Kevin Lokay | M | 67 | 6 years | |
| Ankit Mahadevia | M | 43 |
The Johns Hopkins University
| - |
| James G. Lazar | M | - |
The Johns Hopkins University
| - |
| Michael Caloyannides | M | - |
The Johns Hopkins University
| - |
| Charles G. Drake | M | 83 |
The Johns Hopkins University
| - |
| Rajeev Kumar Goel | M | 46 |
The Johns Hopkins University
| - |
| Barclay Knapp | M | 67 |
The Johns Hopkins University
| - |
| Scott Semple | M | - |
The Johns Hopkins University
| - |
| Amy Ong Tsui | M | - |
The Johns Hopkins University
| - |
| Donald J. Shepard | M | 77 |
The Johns Hopkins University
| - |
| N. Coles | M | 63 |
The Johns Hopkins University
| - |
| Charles Kahn | M | 72 |
The Johns Hopkins University
| - |
| Charles I. Clarvit | M | 68 |
The Johns Hopkins University
| - |
| Christina Roskovich | F | - |
The Johns Hopkins University
| - |
| Thomas Graham | M | - |
The Johns Hopkins University
| - |
| Kathleen L. Kiernan | M | - |
The Johns Hopkins University
| - |
| Ethan D. Leder | M | - |
The Johns Hopkins University
| - |
| Fouad Ajami | M | - |
The Johns Hopkins University
| - |
| Susan Mary Galbraith | M | - | 14 years | |
| Mike Armstrong | M | 85 |
The Johns Hopkins University
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Wayne T. Hockmeyer | M | 79 |
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | 19 years |
| Joseph Swedish | M | 72 | 5 years | |
| David Mott | M | 58 |
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | 16 years |
| Howard H. Pien | M | 66 |
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | 3 years |
| Simon Lowth | M | 62 | 6 years | |
| Julie Brown | F | 62 | 14 years | |
| Leif Valdemar Johansson | M | 73 | 11 years | |
| Sean P. Lance | M | 77 |
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | 6 years |
| Gloria McCarthy | F | 71 | 18 years | |
| David Brennan | M | 70 | 13 years | |
| John Gallina | M | 64 | 15 years | |
| Reginald Seeto | M | 52 |
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | 8 years |
| Louis Schweitzer | M | 80 | 8 years | |
| Dennis Deng | M | - |
The Johns Hopkins University
| 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 76 | 76.00% |
| United Kingdom | 31 | 31.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Bahija Jallal
- Personal Network
